Dmitriy V Ivashchenko

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3494538/publications.pdf

Version: 2024-02-01

18	125	1683354 5	1281420 11
papers	citations	h-index	g-index

20	20	20	278
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes. Drug Metabolism and Personalized Therapy, 2022, 37, 47-53.	0.3	1
2	Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team. British Journal of Clinical Pharmacology, 2021, 87, 725-729.	1.1	1
3	CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes. Drug Metabolism and Personalized Therapy, 2021, .	0.3	1
4	Analysis of associations between pharmacodynamic genetic factors and antipsychoticsâ€™ effectiveness and safety in adolescents with acute psychotic episodes taking antipsychotics during a 28-day follow-up. Kachestvennaya Klinicheskaya Praktika, 2021, , 78-88.	0.2	0
5	Associations of CYP2D6, ABCB1 2677G>T/A and 3435C>T with effectiveness and safety of pharmacotherapy for acute psychotic episodes in adolescents over 28 days. Kachestvennaya Klinicheskaya Praktika, 2021, , 39-49.	0.2	0
6	CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 29-37.	0.4	10
7	Pain pharmacogenetics. Drug Metabolism and Personalized Therapy, 2020, 35, .	0.3	1
8	Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14Âdays after admission: effectiveness and safety evaluation. Drug Metabolism and Personalized Therapy, 2020, 35, .	0.3	6
9	Current and future use of umifenovir in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 75-80.	0.2	1
10	Cognitive impairment in patients with treatment resistant schizophrenia: Associations with DRD2, DRD3, HTR2A, BDNF and CYP2D6 genetic polymorphisms. Neurology Psychiatry and Brain Research, 2019, 33, 48-55.	2.0	8
11	Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: focus on direct oral anticoagulants. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2019, 74, 299-306.	0.2	1
12	Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metabolism and Personalized Therapy, 2018, 33, 65-73.	0.3	10
13	Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metabolism and Personalized Therapy, 2018, 33, 91-98.	0.3	6
14	IMPACT OF CYP3A5, CYP2C9, CYP2C19, AND CYP2D6 POLYMORPHISMS ON PHENAZEPAM SAFETY IN PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2018, 73, 206-214.	0.2	1
15	Pharmacogenetic evaluation of adverse eventsâ€™ risk in patients with alcohol withdrawal syndrome taking bromdihydrochlorphenylbenzodiazepine: The role of CYP2C19 gene polymorphisms. World Journal of Personalized Medicine, 2017, 1, 18-26.	0.3	1
16	The association of polymorphisms in DAT (40â€‰bp VNTR, C>T 3â€²UTR) and DBH (â¯1021 C/T) genes with the severe complications of alcohol withdrawal state. Psychiatric Genetics, 2015, 25, 268-269.	0.6	5
17	Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects. Frontiers in Physiology, 2015, 6, 139.	1.3	64
18	The Frequency of CYP2C9, VKORC1, and CYP4F2 Polymorphisms in Russian Patients With High Thrombotic Risk. Medicina (Lithuania), 2013, 49, 81.	0.8	5